Developed by Janssen Pharmaceuticals, SPRAVATO® is an FDA-approved medication that has shown promising results in treating treatment-resistant depression.
If you or a loved one have been living with depression and have not found relief with traditional antidepressant therapies, SPRAVATO® may be the solution you’ve been searching for.
With its unique mechanism of action, SPRAVATO® has helped countless individuals reclaim their lives and find hope for a brighter future. Keep reading to learn more about this life-changing treatment.
A low dose of SPRAVATO® will be administered via intranasal spray. After five minutes another small dose will be administered. Your provider will monitor you for a two-hour waiting period. We encourage you to wear eyeshades, listen to relaxing music, and focus inward during this time.
You will be monitored very closely during your SPRAVATO® treatment. This will include blood pressure, pulse measurements, and some psychological measurements before and after your session.
SPRAVATO®’s side effects wear off quite quickly; you will be able to return home about 2 hours after treatment is complete. Patients are required to have another person drive them home. You should not drive until the next day after a restful sleep.
During treatment, patients may experience an altered or dream like state, which most describe as very pleasing.
We understand that navigating insurance coverage for SPRAVATO® can be a source of stress for our patients. At our office, we are committed to making this process as seamless as possible. While some insurance providers do cover SPRAVATO®, others may not.
Rest assured that our team is actively working to determine which insurance providers cover SPRAVATO® and fighting to obtain answers for our patients. We believe that access to life-changing treatments like SPRAVATO® should not be hindered by insurance coverage, and we are dedicated to advocating for our patients every step of the way.
You may qualify if you have tried at least 2 Antidepressants without any success.
SPRAVATO® is specifically intended for adult individuals who are grappling with severe symptoms associated with major depressive disorders, including suicidal thoughts and behaviors. Additionally, it is intended for those experiencing treatment-resistant depression, a condition that can only be diagnosed and evaluated by a qualified medical professional.
If you have undergone two or more preliminary depression treatments, such as talk therapy and prescription medications, or more advanced therapies like TMS or standard ketamine therapy, without any sustained relief or positive outcomes, then SPRAVATO® could potentially be the ideal solution for you.
The first step towards receiving SPRAVATO® treatment involves undergoing a comprehensive psychiatric evaluation, which is fully covered by insurance. This assessment will help determine if SPRAVATO® is a suitable treatment option for you, especially if you have been diagnosed with treatment-resistant depression and have previously attempted two or more unsuccessful treatments.
Once it is established that SPRAVATO® is the best course of action, our certified technicians will provide a thorough explanation of the treatment process and important safety considerations to ensure you are fully informed about what to expect.
During each treatment session, our qualified clinicians will supervise you as you administer the SPRAVATO® nasal spray, demonstrating the correct technique. Following administration, you will be asked to rest comfortably while our staff monitors you closely for any potential side effects. After a two-hour observation period, our technicians will conclude the session, and you will be free to leave.
If you have treatment-resistant depression and want symptom relief, turn to Serenity Health in Louisville, KY, for exceptional care. Our expert team offers SPRAVATO® nasal spray for the treatment of depression and other mental health disorders you might encounter. Call the office to learn more about this revolutionary treatment, or book an appointment online today.